MetLife Investment Advisors LLC Reduces Position in Voyager Therapeutics Inc (VYGR)

MetLife Investment Advisors LLC decreased its stake in shares of Voyager Therapeutics Inc (NASDAQ:VYGR) by 41.0% in the fourth quarter, Holdings Channel reports. The fund owned 10,649 shares of the company’s stock after selling 7,401 shares during the period. MetLife Investment Advisors LLC’s holdings in Voyager Therapeutics were worth $100,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Bank of America Corp DE boosted its position in shares of Voyager Therapeutics by 211.0% during the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock worth $100,000 after acquiring an additional 7,217 shares during the last quarter. AlphaCrest Capital Management LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter worth $102,000. Weiss Multi Strategy Advisers LLC lifted its position in Voyager Therapeutics by 10.0% during the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 11,000 shares of the company’s stock valued at $103,000 after purchasing an additional 1,000 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Voyager Therapeutics by 66.8% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after purchasing an additional 4,559 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Voyager Therapeutics by 24.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 12,800 shares of the company’s stock valued at $120,000 after purchasing an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 85.18% of the company’s stock.

In other news, major shareholder Neurocrine Biosciences Inc bought 4,179,728 shares of Voyager Therapeutics stock in a transaction dated Tuesday, March 12th. The shares were acquired at an average price of $11.96 per share, with a total value of $49,989,546.88. Following the completion of the purchase, the insider now owns 4,179,728 shares in the company, valued at approximately $49,989,546.88. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 33.60% of the company’s stock.

Several equities analysts have commented on VYGR shares. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a research report on Saturday, January 19th. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, January 15th. Cowen reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, February 27th. ValuEngine upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, March 15th. Finally, BidaskClub upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $24.00.

VYGR stock opened at $21.37 on Monday. Voyager Therapeutics Inc has a 52 week low of $7.76 and a 52 week high of $24.24. The firm has a market cap of $787.08 million, a price-to-earnings ratio of -7.77 and a beta of 2.83.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, February 26th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.04). Voyager Therapeutics had a negative net margin of 1,158.79% and a negative return on equity of 120.82%. The firm had revenue of $2.01 million during the quarter, compared to analysts’ expectations of $2.90 million. On average, equities research analysts forecast that Voyager Therapeutics Inc will post -2.79 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “MetLife Investment Advisors LLC Reduces Position in Voyager Therapeutics Inc (VYGR)” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2019/04/29/metlife-investment-advisors-llc-reduces-position-in-voyager-therapeutics-inc-vygr.html.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Featured Story: What is a Lock-Up Period?

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.